RESUMO
Partially purified ginsenoside extract (PGE) and compound K enriched extract (CKE) were prepared from ginseng sprouts, and their antioxidant, anti-inflammatory and antithrombotic effects were investigated. Compared to the 6-year-old ginseng roots, ginseng sprouts were found to have a higher content of phenolic compounds, saponin and protopanaxadiol-type ginsenoside by about 56%, 36% and 43%, respectively. PGE was prepared using a macroporous adsorption resin, and compound K(CK) was converted and enriched from the PGE by enzymatic hydrolysis with a conversion rate of 75%. PGE showed higher effects than CKE on radical scavenging activity in antioxidant assays. On the other hand, CKE reduced nitric oxide levels more effectively than PGE in RAW 264.7 cells. CKE also reduced pro-inflammatory cytokines, such as tumor necrosis factor-α, interleukin (IL)-1ß and IL-6 than PGE. Tail bleeding time and volume were investigated after administration of CKE at 70-150 mg/kg/day to mice. CKE administered group showed a significant increase or increased tendency in bleeding time than the control group. Bleeding volume in the CKE group increased than the control group, but not as much as in the aspirin group. In conclusion, ginseng sprouts could be an efficient source of ginsenoside, and CKE converted from the ginsenosides showed antioxidant, anti-inflammatory and antithrombotic effects. However, it was estimated that the CKE might play an essential role in anti-inflammatory effects rather than antioxidant effects.
Assuntos
Anti-Inflamatórios/farmacologia , Antioxidantes/farmacologia , Fibrinolíticos/farmacologia , Ginsenosídeos/farmacologia , Panax/química , Extratos Vegetais/farmacologia , Animais , Citocinas/metabolismo , Hemorragia/tratamento farmacológico , Camundongos , Camundongos Endogâmicos ICR , Óxido Nítrico/metabolismo , Células RAW 264.7RESUMO
Although diabetic peripheral neuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN) are different disease entities, they share similar neuropathic symptoms that impede quality of life for these patients. Despite having very similar downstream effects, there have been no direct comparisons between DPN and CIPN with respect to symptom severity and therapeutic responses. We compared peripheral nerve damage due to hyperglycemia with that caused by paclitaxel (PAC) treatment as represented by biochemical parameters, diverse sensory tests, and immunohistochemistry of cutaneous and sciatic nerves. The therapeutic effects of alpha-lipoic acid and DA-9801 were also compared in the two models. Animals were divided into seven groups (n = 7-10) as follows: normal, diabetes (DM), DM + alpha-lipoic acid 100 mg/kg (ALA), DM + DA-9801 (100 mg/kg), paclitaxel-treated rat (PAC), PAC + ALA (100 mg/kg), and PAC + DA-9801 (100 mg/kg). The sensory thresholds of animals to mechanical, heat, and pressure stimuli were altered by both hyperglycemia and PAC when compared with controls, and the responses to sensory tests were different between both groups. There were no significant differences in the biochemical markers of blood glutathione between DM and PAC groups (p > .05). Quantitative comparisons of peripheral nerves by intraepidermal nerve fiber density (IENFD) analysis indicated that the DM and PAC groups were similar (6.18 ± 1.03 vs. 5.01 ± 2.57). IENFD was significantly improved after ALA and DA-9801 treatment in diabetic animals (7.6 ± 1.28, 7.7 ± 1.28, respectively, p < .05) but did not reach significance in the PAC-treated groups (6.05 ± 1.76, 5.66 ± 1.26, respectively, p > .05). Sciatic nerves were less damaged in the PAC-treated groups compared with the DM groups with respect to axonal diameter and area (8.60 ± 1.14 µm vs. 6.66 ± 1.07 µm, and 59.04 ± 15.16 µm2 vs. 35.71 ± 11.2 µm2, respectively, p < .05). Based on these results, the neuropathic manifestation and therapeutic responses of DPN may be different from other peripheral neuropathies. Therefore, specific pathogenic consideration according to peripheral neuropathy classification in addition to common treatments needs to be developed for management strategies of peripheral neuropathies.
Assuntos
Diabetes Mellitus Experimental/patologia , Diabetes Mellitus Experimental/fisiopatologia , Limiar da Dor/fisiologia , Doenças do Sistema Nervoso Periférico/patologia , Doenças do Sistema Nervoso Periférico/fisiopatologia , Animais , Antineoplásicos Fitogênicos/farmacologia , Glicemia/efeitos dos fármacos , Peso Corporal/efeitos dos fármacos , Diabetes Mellitus Experimental/tratamento farmacológico , Modelos Animais de Doenças , Glutationa/sangue , Hiperalgesia/fisiopatologia , Interleucina-6/metabolismo , Masculino , Fator de Crescimento Neural/metabolismo , Neuroprostanos/uso terapêutico , Paclitaxel/farmacologia , Limiar da Dor/efeitos dos fármacos , Doenças do Sistema Nervoso Periférico/induzido quimicamente , Doenças do Sistema Nervoso Periférico/tratamento farmacológico , Preparações de Plantas/uso terapêutico , Ratos , Ratos Sprague-Dawley , Nervo Isquiático/efeitos dos fármacos , Nervo Isquiático/metabolismo , Nervo Isquiático/patologia , Ácido Tióctico/uso terapêuticoRESUMO
It has been reported that DA-9801, an extract mixture of Dioscorea japonica Thunb and Dioscorea nipponica Makino, produces a neurotrophic activity. Therefore, this study was conducted to examine the neuroprotective effects of DA-9801 in streptozotocin-induced diabetic rats. The experimental rats were divided into six groups: the control group, Group I (non-diabetic rats treated with DA-9801), Group II (diabetic, non-treated rats) and Groups III, IV, and V (diabetic rats treated with DA-9801 at doses of 10, 50 or 100 mg/kg/d). Following a 16-wk course of oral treatment with DA-9801, functional parameters (von Frey filament test, hot plate test), biochemical parameters (nerve growth factor (NGF), tumor necrosis factor (TNF)-α, interleukin (IL)-6) were measured. An immunohistochemical staining was done to assess the neuroprotective effects of DA-9081 in the skin, sciatic nerve, gastric mucosa and renal cortex. In Week 8, pain was evoked by either tactile or thermal stimuli, whose threshold was significantly higher in Group III, IV and V than Group II. Western blot analysis showed a more significant increase in NGF and decrease in TNF-α and IL-6 in Group III, IV and V than in Group II (p<0.05). Moreover, following the treatment with DA-9801, a loss of intraepidermal nerve fibers (IENFs) was inhibited to a significant level in the skin, myelinated axonal fibers of the sciatic nerve and small nerve fibers innervating the gastric mucosa or renal cortex (p<0.05). Our results demonstrated that DA-9801 is a beneficial agent that protects the peripheral nerves in diabetic rats.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Neuropatias Diabéticas/prevenção & controle , Suplementos Nutricionais , Fator de Crescimento Neural/agonistas , Fármacos Neuroprotetores/uso terapêutico , Sistema Nervoso Periférico/metabolismo , Extratos Vegetais/uso terapêutico , Animais , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/efeitos adversos , Anti-Inflamatórios não Esteroides/metabolismo , Citocinas/antagonistas & inibidores , Citocinas/metabolismo , Diabetes Mellitus Experimental/complicações , Neuropatias Diabéticas/imunologia , Neuropatias Diabéticas/metabolismo , Neuropatias Diabéticas/patologia , Mucosa Gástrica/imunologia , Mucosa Gástrica/inervação , Mucosa Gástrica/metabolismo , Mucosa Gástrica/patologia , Córtex Renal/imunologia , Córtex Renal/inervação , Córtex Renal/metabolismo , Córtex Renal/patologia , Masculino , Fator de Crescimento Neural/metabolismo , Proteínas do Tecido Nervoso/agonistas , Proteínas do Tecido Nervoso/antagonistas & inibidores , Proteínas do Tecido Nervoso/metabolismo , Fármacos Neuroprotetores/administração & dosagem , Fármacos Neuroprotetores/efeitos adversos , Fármacos Neuroprotetores/metabolismo , Limiar da Dor , Sistema Nervoso Periférico/imunologia , Sistema Nervoso Periférico/patologia , Extratos Vegetais/administração & dosagem , Extratos Vegetais/efeitos adversos , Extratos Vegetais/metabolismo , Preparações de Plantas/administração & dosagem , Preparações de Plantas/efeitos adversos , Preparações de Plantas/metabolismo , Preparações de Plantas/uso terapêutico , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley , Nervo Isquiático/imunologia , Nervo Isquiático/metabolismo , Nervo Isquiático/patologia , Pele/imunologia , Pele/inervação , Pele/metabolismo , Pele/patologia , EstreptozocinaRESUMO
BACKGROUND: Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with a very poor prognosis. Several clinical studies such as immunotherapy, gene therapy and molecular targeting agents have been tried for treatment of malignant mesothelioma, however, there is no application for effective clinical treatment. Coffee has various biological functions such as anti-oxidant, anti-inflammatory, anti-mutagenic and anti-carcinogenic activities. The therapeutic activities of the bioactive compounds in coffee was sugested to influence intracellular signaling of MPM. Regarding to the cancer-related functions, In this study, suppression of Sp1 protein level followed by induction of MSTO-211H cell apoptosis by cafestol and kahweol were investigated in oreder to determine Sp1's potential as a significant target for human MPM therapy as well. METHODS: Cells were treated separately with final concentration of cafestol and kahweol and the results were analyzed by MTS assay, DAPI staining, PI staining, luciferase assay, RT-PCR, and immunoblotting. RESULTS: Viability of MSTO-211H and H28 cells were decreased, and apoptotic cell death was increased in MSTO-211H as a result of cafestol and kahweol treatment. Cafestol and kahweol increased Sub-G1 population and nuclear condensation in MSTO-211H cells. Roles of Sp1 in cell proliferation and apoptosis of the MSTO-211H cells by the Sp1 inhibitor of Mithramycin A were previously confirmed. Cafestol and kahweol significantly suppressed Sp1 protein levels. Kahweol slightly attenuated Sp1 mRNA, while Cafestol did not affect in MSTO-211H cells. Cafestol and kahweol modulated the promoter activity and protein expression level of the Sp1 regulatory genes including Cyclin D1, Mcl-1, and Survivin in mesothelioma cells. Apoptosis signaling cascade was activated by cleavages of Bid, Caspase-3, and PARP with cafestol and by upregulation of Bax, and downregulation of Bcl-xl by kahweol. CONCLUSIONS: Sp1 can be a novel molecular target of cafestol and kahweol in human MPM.
Assuntos
Apoptose/efeitos dos fármacos , Biomarcadores Tumorais , Café , Diterpenos/administração & dosagem , Neoplasias Pulmonares/metabolismo , Receptores Imunológicos , Biomarcadores Tumorais/genética , Biomarcadores Tumorais/metabolismo , Sobrevivência Celular/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Humanos , Mesotelioma/metabolismo , Receptores Imunológicos/genética , Receptores Imunológicos/metabolismoRESUMO
RATIONALE: Cellular redox homeostasis altered by excessive production of reactive oxygen species (ROS) and weakening of the antioxidant defense leads to oxidative stress. Oxidative stress is characterized as a decrease in glutathione/glutathione disulfide (GSH/GSSG) and the triggering of a number of the redox-sensitive signaling cascades. Recent studies have demonstrated that ROS play an important role in the pathogenesis of airway inflammation and hyperresponsiveness. OBJECTIVES: Here we characterized for the first time the protective properties of a new hydrophobic thiol compound, N-acetyl cysteine proline cysteine amide (CB3), in allergic airway diseases. METHODS: We used ovalbumin (OVA)-inhaled mice to evaluate the role of CB3 as an antiinflammatory reagent and to determine its molecular signaling activity in allergic airways. MEASUREMENTS AND MAIN RESULTS: The administration of CB3 (1-50 mg/kg) to OVA-inhaled mice restored the decreased GSH levels, enhanced IL-10 expression, and significantly reduced the increase of Th2 cytokines and OVA-specific IgE. CB3 decreased the number of inflammatory cells and airway hyperresponsiveness in the lungs. We also found that the administration of CB3 dramatically decreased the nuclear translocation of the nuclear factor-κB (NF-κB) and the phosphorylation of p38 mitogen-activated protein kinases (MAPKs) in lungs after OVA inhalation. In addition, allergen-induced airway inflammation and hyperresponsiveness were substantially reduced by the administration of inhibitors of NF-κB and p38 MAPK, BAY 11-7085, and SB 239063, respectively. CONCLUSIONS: These results suggest that CB3 attenuates allergic airway disease by up-regulation of GSH levels as well as inhibition of NF-κB and p38 MAPK activity.
Assuntos
Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Oligopeptídeos/uso terapêutico , Compostos de Sulfidrila/uso terapêutico , Proteínas Quinases p38 Ativadas por Mitógeno/antagonistas & inibidores , Animais , Hiper-Reatividade Brônquica/tratamento farmacológico , Líquido da Lavagem Broncoalveolar/química , Líquido da Lavagem Broncoalveolar/citologia , Modelos Animais de Doenças , Feminino , Glutationa/análise , Dissulfeto de Glutationa/análise , Imidazóis/farmacologia , Pulmão/química , Camundongos , Camundongos Endogâmicos C57BL , Nitrilas/farmacologia , Pirimidinas/farmacologia , Espécies Reativas de Oxigênio/análise , Sulfonas/farmacologiaRESUMO
Antithrombotic activity of methanolic extract of an edible lichen, Umbilicaria esculenta, was evaluated on platelet aggregation in vitro and pulmonary thrombosis in vivo. The extract showed concentration dependent inhibitory effects on platelet aggregation induced by ADP, with IC(50) value of 2.4 mg/mL. Orally administered extract protected mice against thrombotic death or paralysis induced by collagen and epinephrine in a dose dependent manner. It produced a significant inhibition of thrombotic death or paralysis at over 100 mg/kg body weight, while aspirin produced a significant inhibition of thrombosis at 10-20 mg/kg body weight. Mouse tail bleeding time was significantly prolonged by addition of the extract. On the other hand, the extract did not show any fibrinolytic activity and alter coagulation parameters such as activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) in rat platelet. These results suggested that the antithrombotic activity of Umbilicaria esculenta extract might be due to antiplatelet activity rather than anticoagulation activity.
Assuntos
Fibrinolíticos/farmacologia , Líquens , Inibidores da Agregação Plaquetária/farmacologia , Animais , Relação Dose-Resposta a Droga , Líquens/química , Masculino , Camundongos , Camundongos Endogâmicos ICR , Agregação Plaquetária/efeitos dos fármacos , Ratos , Ratos Sprague-DawleyRESUMO
The antiplatelet and antithrombotic activities of a methanol extract of a medicinal lichen, Usnea longissima, were investigated on platelet aggregation in vitro and on pulmonary thrombosis in vivo. The extract showed concentration dependent inhibitory effects on ADP-induced platelet aggregation, with an IC50 value of 3.6 mg/mL. Using an in vivo mouse thrombotic model in which mice were challenged with an intravenous injection of collagen and epinephrine mixture, oral administration of the extract prior to the injection produced a significant inhibition of thrombotic death or paralysis at 100-200 mg/kg body weight. Aspirin, a representative antiplatelet drug, produced a significant inhibition of thrombotic death at 10-20 mg/kg body weight. The mouse tail bleeding time was significantly prolonged by the addition of the extract. On the other hand, the extract did not show any fibrinolytic activity or alter the coagulation parameters such as activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) in rat platelets in vitro. These results suggested that the antithrombotic activity of U. longissima extract might be due to antiplatelet activity rather than anticoagulant activity.